Homology Medicines Inc reports results for the quarter ended in September - Earnings Summary

Q32 Bio

14/11/2022 14:32

* Homology Medicines Inc  FIXX.OQ  reported a quarterly
adjusted
loss of 59 cents​​ per share for the quarter ended in September.
The mean expectation of ten analysts for the quarter was for a
loss of 47 cents per share.
    * Revenue fell 52.2% to $802.00 thousand from a year ago;
analysts
expected $860.40 thousand. 
    * Homology Medicines Inc's reported EPS for the quarter was
a loss
of 59 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Homology Medicines Inc shares had fallen by 6.8% this
quarter and lost 58.8% so far this year.
    * The company reported a quarterly loss of $33.73 million.
    * Wall Street's median 12-month price target for Homology
Medicines Inc is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 02:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.47          -0.59          Missed
 Jun. 30 2022      -0.56          -0.51          Beat
 Mar. 31 2022      -0.35          -0.20          Beat
 Dec. 31 2021      -0.59          -0.59          Met